Distinct phosphorylation clusters determine the signaling outcome of free fatty acid receptor 4/g protein-coupled receptor 120

Molecular Pharmacology

Volumn 89, Issue 5, 2016, Pages 505-520

  Prihandoko, Rudi ^a   Alvarez Curto, Elisa ^b   Hudson, Brian D ^b   Butcher, Adrian J ^a   Ulven, Trond ^c   Miller, Ashley M ^b   Tobin, Andrew B ^a   Milligan, Graeme ^b  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ARRESTIN 3; G PROTEIN COUPLED RECEPTOR 120; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; RETINA S ANTIGEN; SERINE; THREONINE; UNCLASSIFIED DRUG; AGENTS AFFECTING WATER, MOLECULE OR ION TRANSPORT; AKT1 PROTEIN, MOUSE; ARRESTIN3; BACTERIAL PROTEIN; ENZYME INHIBITOR; G PROTEIN COUPLED RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; HYBRID PROTEIN; O3FAR1 PROTEIN, MOUSE; PHOTOPROTEIN; YELLOW FLUORESCENT PROTEIN, BACTERIA;

ANIMAL CELL; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; INTERNALIZATION; MASS SPECTROMETRY; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; AGONISTS; AMINO ACID SUBSTITUTION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL MEMBRANE; CHEMISTRY; CHO CELL LINE; CRICETULUS; DRUG EFFECTS; ENZYMOLOGY; GENETICS; HEK293 CELL LINE; HUMAN; METABOLISM; MOUSE; PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION;

AMINO ACID SUBSTITUTION; ANIMALS; ARRESTINS; BACTERIAL PROTEINS; CELL MEMBRANE; CHO CELLS; CRICETULUS; ENZYME ACTIVATION; ENZYME INHIBITORS; GTP-BINDING PROTEIN ALPHA SUBUNITS, GQ-G11; HEK293 CELLS; HUMANS; LUMINESCENT PROTEINS; MAP KINASE SIGNALING SYSTEM; MEMBRANE TRANSPORT MODULATORS; MICE; MUTATION; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, G-PROTEIN-COUPLED; RECOMBINANT FUSION PROTEINS; SERINE; THREONINE;

EID: 84963864551     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.115.101949     Document Type: Article

References (48)

1. Bonnefond A, Lamri A, Leloire A, Vaillant E, Roussel R, Lévy-Marchal C, Weill J, Galan P, Hercberg S, and Ragot S et al. (2015) Contribution of the low-frequency, loss-of-function p. R270H mutation in FFAR4 (GPR120) to increased fasting plasma glucose levels. J Med Genet 52:595-598.
2. Butcher AJ, Hudson BD, Shimpukade B, Alvarez-Curto E, Prihandoko R, Ulven T, Milligan G, and Tobin AB (2014) Concomitant action of structural elements and receptor phosphorylation determines arrestin-3 interaction with the free fatty acid receptor FFA4. J Biol Chem 289:18451-18465.
3. Butcher AJ, Prihandoko R, Kong KC, McWilliams P, Edwards JM, Bottrill A, Mistry S, and Tobin AB (2011) Differential G-protein-coupled receptor phosphorylation provides evidence for a signaling bar code. J Biol Chem 286:11506-11518.
4. Canals M, Jenkins L, Kellett E, and Milligan G (2006) Up-regulation of the angiotensin II type 1 receptor by the MAS proto-oncogene is due to constitutive activation of Gq/G11 by MAS. J Biol Chem 281:16757-16767.
5. Cianfrocca R, Rosanò L, Spinella F, Di Castro V, Natali PG, and Bagnato A (2010) Beta-arrestin-1 mediates the endothelin-1-induced activation of Akt and integrinlinked kinase. Can J Physiol Pharmacol 88:796-801.
6. Dranse HJ, Kelly ME, and Hudson BD (2013) Drugs or diet?-Developing novel therapeutic strategies targeting the free fatty acid family of GPCRs. Br J Pharmacol 170:696-711.
7. Engelstoft MS, Park WM, Sakata I, Kristensen LV, Husted AS, Osborne-Lawrence S, Piper PK, Walker AK, Pedersen MH, and Nøhr MK et al. (2013) Seven transmembrane G protein-coupled receptor repertoire of gastric ghrelin cells. Mol Metab 2:376-392.
8. Hara T, Kashihara D, Ichimura A, Kimura I, Tsujimoto G, and Hirasawa A (2014) Role of free fatty acid receptors in the regulation of energy metabolism. Biochim Biophys Acta 1841:1292-1300.
9. Hirasawa A, Tsumaya K, Awaji T, Katsuma S, Adachi T, Yamada M, Sugimoto Y, Miyazaki S, and Tsujimoto G (2005) Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat Med 11:90-94.
10. Hudson BD, Shimpukade B, Milligan G, and Ulven T (2014) The molecular basis of ligand interaction at free fatty acid receptor 4 (FFA4/GPR120). J Biol Chem 289:20345-20358.
11. Ichimura A, Hasegawa S, Kasubuchi M, and Kimura I (2014) Free fatty acid receptors as therapeutic targets for the treatment of diabetes. Front Pharmacol 5:236.
12. Ichimura A, Hirasawa A, Poulain-Godefroy O, Bonnefond A, Hara T, Yengo L, Kimura I, Leloire A, Liu N, and Iida K et al. (2012) Dysfunction of lipid sensor GPR120 leads to obesity in both mouse and human. Nature 483:350-354.
13. Im DS (2015) Functions of omega-3 fatty acids and FFA4 (GPR120) in macrophages. Eur J Pharmacol DOI:10.1016/j.ejphar.2015.03.094 [published ahead of print].
14. Iwasaki K, Harada N, Sasaki K, Yamane S, Iida K, Suzuki K, Hamasaki A, Nasteska D, Shibue K, and Joo E et al. (2015) Free fatty acid receptor GPR120 is highly expressed in enteroendocrine K cells of the upper small intestine and has a critical role in GIP secretion after fat ingestion. Endocrinology 156:837-846.
15. Jenkins L, Brea J, Smith NJ, Hudson BD, Reilly G, Bryant NJ, Castro M, Loza MI, and Milligan G (2010) Identification of novel species-selective agonists of the G-protein-coupled receptor GPR35 that promote recruitment of b-arrestin-2 and activate Ga13. Biochem J 432:451-459.
16. Kaku K, Enya K, Nakaya R, Ohira T, and Matsuno R (2015) Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial. Diabetes Obes Metab 17:675-681.
17. Kendall RT, Lee MH, Pleasant DL, Robinson K, Kuppuswamy D, McDermott PJ, and Luttrell LM (2014) Arrestin-dependent angiotensin AT1 receptor signaling regulates Akt and mTor-mediated protein synthesis. J Biol Chem 289:26155-26166.
18. Kong KC, Butcher AJ, McWilliams P, Jones D, Wess J, Hamdan FF, Werry T, Rosethorne EM, Charlton SJ, and Munson SE et al. (2010) M3-muscarinic receptor promotes insulin release via receptor phosphorylation/arrestin-dependent activation of protein kinase D1. Proc Natl Acad Sci USA 107:21181-21186.
19. Liu HD, Wang WB, Xu ZG, Liu CH, He DF, Du LP, Li MY, Yu X, and Sun JP (2015) FFA4 receptor (GPR120): a hot target for the development of anti-diabetic therapies. Eur J Pharmacol 763:160-168.
20. Luttrell LM and Gesty-Palmer D (2010) Beyond desensitization: physiological relevance of arrestin-dependent signaling. Pharmacol Rev 62:305-330.
21. Luttrell LM, Maudsley S, and Bohn LM (2015) Fulfilling the promise of "biased" G protein-coupled receptor agonism. Mol Pharmacol 88:579-588.
22. MacKenzie AE, Caltabiano G, Kent TC, Jenkins L, McCallum JE, Hudson BD, Nicklin SA, Fawcett L, Markwick R, and Charlton SJ et al. (2014) The antiallergic mast cell stabilizers lodoxamide and bufrolin as the first high and equipotent agonists of human and rat GPR35. Mol Pharmacol 85:91-104.
23. Mancini AD and Poitout V (2013) The fatty acid receptor FFA1/GPR40 a decade later: how much do we know? Trends Endocrinol Metab 24:398-407.
24. Mancini AD and Poitout V (2015) GPR40 agonists for the treatment of type 2 diabetes: life after 'TAKing' a hit. Diabetes Obes Metab 17:622-629.
25. Marchese A, Paing MM, Temple BR, and Trejo J (2008) G protein-coupled receptor sorting to endosomes and lysosomes. Annu Rev Pharmacol Toxicol 48:601-629.
26. Milligan G, Alvarez-Curto E, Watterson KR, Ulven T, and Hudson BD (2015) Characterizing pharmacological ligands to study the long-chain fatty acid receptors GPR40/FFA1 and GPR120/FFA4. Br J Pharmacol 172:3254-3265.
27. Nishimura A, Kitano K, Takasaki J, Taniguchi M, Mizuno N, Tago K, Hakoshima T, and Itoh H (2010) Structural basis for the specific inhibition of heterotrimeric Gq protein by a small molecule. Proc Natl Acad Sci USA 107:13666-13671.
28. Nobles KN, Xiao K, Ahn S, Shukla AK, Lam CM, Rajagopal S, Strachan RT, Huang TY, Bressler EA, and Hara MR et al. (2011) Distinct phosphorylation sites on the b (2)-adrenergic receptor establish a barcode that encodes differential functions of b-arrestin. Sci Signal 4: ra51.
29. Offermanns S (2014) Free fatty acid (FFA) and hydroxy carboxylic acid (HCA) receptors. Annu Rev Pharmacol Toxicol 54:407-434.
30. Oh DY, Talukdar S, Bae EJ, Imamura T, Morinaga H, Fan W, Li P, Lu WJ, Watkins SM, and Olefsky JM (2010) GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell 142:687-698.
31. Oh Y, Walenta E, Akiyama TE, Lagakos WS, Lackey D, Pessentheiner AR, Sasik R, Hah N, Chi TJ, and Cox JM et al. (2014) A Gpr120-selective agonist improves insulin resistance and chronic inflammation in obese mice. Nat Med 20:942-947.
32. Ohguro H, Palczewski K, Ericsson LH, Walsh KA, and Johnson RS (1993) Sequential phosphorylation of rhodopsin at multiple sites. Biochemistry 32:5718-5724.
33. Parker HE, Habib AM, Rogers GJ, Gribble FM, and Reimann F (2009) Nutrientdependent secretion of glucose-dependent insulinotropic polypeptide from primary murine K cells. Diabetologia 52:289-298.
34. Reiter E and Lefkowitz RJ (2006) GRKs and beta-arrestins: roles in receptor silencing, trafficking and signaling. Trends Endocrinol Metab 17:159-165.
35. Sekiguchi H, Kasubuchi M, Hasegawa S, Pelisch N, Kimura I, and Ichimura A (2015) A novel antidiabetic therapy: free fatty acid receptors as potential drug target. Curr Diabetes Rev 11:107-115.
36. Shenoy SK and Lefkowitz RJ (2011) b-Arrestin-mediated receptor trafficking and signal transduction. Trends Pharmacol Sci 32:521-533.
37. Shimpukade B, Hudson BD, Hovgaard CK, Milligan G, and Ulven T (2012) Discovery of a potent and selective GPR120 agonist. J Med Chem 55:4511-4515.
38. Shukla AK, Manglik A, Kruse AC, Xiao K, Reis RI, Tseng WC, Staus DP, Hilger D, Uysal S, and Huang LY et al. (2013) Structure of active b-arrestin-1 bound to a G-protein-coupled receptor phosphopeptide. Nature 497:137-141.
39. Sparks SM, Chen G, Collins JL, Danger D, Dock ST, Jayawickreme C, Jenkinson S, Laudeman C, Leesnitzer MA, and Liang X et al. (2014) Identification of diarylsulfonamides as agonists of the free fatty acid receptor 4 (FFA4/GPR120). Bioorg Med Chem Lett 24:3100-3103.
40. Stone VM, Dhayal S, Brocklehurst KJ, Lenaghan C, Sörhede Winzell M, Hammar M, Xu X, Smith DM, and Morgan NG (2014) GPR120 (FFAR4) is preferentially expressed in pancreatic delta cells and regulates somatostatin secretion from murine islets of Langerhans. Diabetologia 57:1182-1191.
41. Suckow AT, Polidori D, Yan W, Chon S, Ma JY, Leonard J, and Briscoe CP (2014) Alteration of the glucagon axis in GPR120 (FFAR4) knockout mice: a role for GPR120 in glucagon secretion. J Biol Chem 289:15751-15763.
42. Takasaki J, Saito T, Taniguchi M, Kawasaki T, Moritani Y, Hayashi K, and Kobori M (2004) A novel Galphaq/11-selective inhibitor. J Biol Chem 279:47438-47445.
43. Thompson GL, Canals M, and Poole DP (2014) Biological redundancy of endogenous GPCR ligands in the gut and the potential for endogenous functional selectivity. Front Pharmacol 5:262.
44. Tobin AB (2008) G-protein-coupled receptor phosphorylation: where, when and by whom. Br J Pharmacol 153(Suppl 1):S167-S176.
45. Tobin AB, Butcher AJ, and Kong KC (2008) Location, location, location...site-specific GPCR phosphorylation offers a mechanism for cell-type-specific signalling. Trends Pharmacol Sci 29:413-420.
46. Violin JD, Crombie AL, Soergel DG, and Lark MW (2014) Biased ligands at G-protein-coupled receptors: promise and progress. Trends Pharmacol Sci 35:308-316.
47. Watterson KR, Hudson BD, Ulven T, and Milligan G (2014) Treatment of type 2 diabetes by free fatty acid receptor agonists. Front Endocrinol (Lausanne) 5:137.
48. Zhuo Y, Vishnivetskiy SA, Zhan X, Gurevich VV, and Klug CS (2014) Identification of receptor binding-induced conformational changes in non-visual arrestins. J Biol Chem 289:20991-21002.